



## **Progen Pharmaceuticals to present at the Bell Potter Emerging Companies Conference**

**Brisbane, Australia. 13 June 2007:** Progen Pharmaceuticals Limited (ASX: PGL; NASDAQ: PGLA) will present today, 13 June 2007 at the Bell Potter Emerging Companies Conference in Melbourne.

The presentation will be available at 11:45 AM today, Brisbane EST, on Progen's website [www.progen-pharma.com](http://www.progen-pharma.com).

**About Progen:** Progen Pharmaceuticals Limited (formerly Progen Industries Limited) is an Australian-based globally focused biotechnology company committed to the discovery, development and commercialisation of small molecule therapeutics primarily for the treatment of cancer.

### **Progen Information:**

Justus Homburg  
Progen Pharmaceuticals Limited  
T: +61 7 3842 3333  
E: justush@progen-pharma.com

Noreen Dillane  
Progen Pharmaceuticals Limited  
T: +61 7 3842 3333  
E: noreend@progen-pharma.com

### **Media and Investor Relations Australia:**

Rebecca Piercy  
Buchan Consulting  
T: +61 2 9237 2800 / 0422 916 422  
E: rpiercy@bcg.com.au

Rebecca Wilson  
Buchan Consulting  
T: +61 417 382 391  
E: rwilson@bcg.com.au

### **Media Relations USA:**

Robert D. Stanislaro  
FD  
T: 212-850-5657  
E: robert.stanislaro@fd.com

### **Investor Relations USA:**

Evan Smith  
FD  
T: 212-850-5606  
E: Evan.smith@fd.com

This press release contains forward-looking statements that are based on current management expectations. These statements may differ materially from actual future events or results due to certain risks and uncertainties, including without limitation, risks inherent in the extensive regulatory approval process mandated by the United States Food and Drug Administration and the Australian Therapeutic Goods Administration prior to the commercialization of any of our product candidates, including PI-88, the risk that the Phase 2 study results described herein are not predictive of the Phase 3 studies which we intend to initiate, risks attendant to delays in obtaining the necessary approvals for clinical testing of our product candidates, risks associated with delays in patient recruitment for our planned Phase 3 clinical and other trials, delays in the conduct and completion of our clinical trials, in particular our planned phase 3 clinical trials for PI-88, risks associated with our failure to demonstrate adequate efficacy and safety data in our planned phase 3 clinical trials to advance the development of PI-88, risks associated with our inability or failure to meet applicable regulatory standards and receive regulatory approval for commercialization of PI-88, risks associated with the market acceptance of PI-88, PI-166 and any of our other product candidates, if approved for commercialization, risks associated with our inability to manufacture or otherwise obtain adequate supplies of PI-88, our future capitals needs, general economic conditions, and other risks and uncertainties detailed from time to time in our filings with the Australian Stock Exchange and the United States Securities and Exchange Commission. Moreover, there can be no assurance that others will not independently develop similar products or processes or design around patents owned or licensed by the Company, or that patents owned or licensed by the Company will provide meaningful protection or competitive advantages.